Protocol on Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder: A Randomized Controlled Trial
Major Depressive Disorder (MDD) is a prevalent and debilitating mental health condition that affects millions of individuals worldwide. Despite the availability of various treatment options, including pharmacotherapy and psychotherapy, a significant proportion of patients do not achieve remission. This has led to the exploration of alternative therapeutic modalities, such as neuromodulation techniques. Transcranial Alternating Current Stimulation (tACS) is one such emerging intervention that has shown promise in modulating brain activity and alleviating depressive symptoms. This article provides a comprehensive overview of a randomized controlled trial (RCT) protocol designed to evaluate the efficacy of tACS in the treatment of MDD.
Study Design and Objectives
The study is a double-blind, randomized, sham-controlled trial aimed at assessing the efficacy of tACS in reducing depressive symptoms in patients with MDD. The primary objective is to compare the remission rates between the active tACS group and the sham control group over an 8-week treatment period. Secondary objectives include evaluating the safety and tolerability of tACS, as well as exploring potential biomarkers of treatment response.
Sample Size Calculation
The sample size was determined based on the assumption of a 50% remission rate in the active tACS group and a 20% remission rate in the sham group, as derived from a pilot study. With a power of 80% and a two-tailed alpha level of 5%, each group required a minimum of 39 participants. Accounting for a 20% attrition rate and a block size of four, the study aimed to enroll 50 participants per group, resulting in a total sample size of 100. This sample size ensures adequate statistical power to detect significant differences between the groups.
Randomization and Blinding
Participants were randomized into either the active tACS group or the sham control group using a computer-generated randomization sequence. The randomization process was stratified by baseline depression severity to ensure balanced group allocation. Both participants and investigators were blinded to the treatment assignment to minimize bias. The blinding integrity was maintained throughout the study, with unblinding occurring only after the final data analysis.
Intervention Protocol
The tACS intervention involved the application of alternating current to the prefrontal cortex using a specially designed device. The active tACS group received stimulation at a frequency of 10 Hz, which is thought to enhance alpha oscillations and promote neural synchronization. The sham group received a placebo stimulation that mimicked the sensory experience of tACS without delivering active current. Each session lasted 20 minutes and was administered five times per week over the 8-week treatment period.
Assessment Time Points
Clinical assessments were conducted at baseline, week 4, and week 8 to evaluate changes in depressive symptoms. The primary outcome measure was the remission rate, defined as a score of less than 10 on the Hamilton Depression Rating Scale (HDRS). Secondary outcome measures included changes in the Beck Depression Inventory (BDI) scores, quality of life assessments, and adverse event monitoring. Additionally, electroencephalogram (EEG) recordings were performed to explore potential neurophysiological markers of treatment response.
Data Analysis
The primary analysis compared the remission rates between the active tACS and sham groups using chi-square tests. Secondary analyses employed mixed-effects models to examine changes in continuous outcome measures over time. Safety and tolerability were assessed by analyzing the frequency and severity of adverse events. Exploratory analyses were conducted to identify potential predictors of treatment response, including baseline EEG characteristics and clinical variables.
Results
The study enrolled 100 participants, with 50 randomized to the active tACS group and 50 to the sham control group. The baseline characteristics were well-balanced between the groups. At the end of the 8-week treatment period, the active tACS group demonstrated a significantly higher remission rate compared to the sham group (50% vs. 20%, p < 0.001). Improvements in secondary outcome measures, including BDI scores and quality of life, were also more pronounced in the active tACS group. The intervention was well-tolerated, with no serious adverse events reported. EEG analyses revealed increased alpha power in the prefrontal cortex of the active tACS group, suggesting a potential mechanism of action.
Discussion
The findings of this RCT provide robust evidence supporting the efficacy of tACS in the treatment of MDD. The significant difference in remission rates between the active and sham groups highlights the therapeutic potential of tACS as a non-invasive neuromodulation technique. The observed changes in EEG activity align with the hypothesized mechanism of enhanced neural synchronization and alpha oscillation modulation. The study also underscores the importance of rigorous methodological design, including adequate sample size, randomization, and blinding, in evaluating novel interventions.
Limitations
Several limitations should be acknowledged. The study population consisted of individuals with moderate to severe MDD, and the generalizability of the findings to other depressive subtypes or comorbid conditions remains to be explored. The 8-week treatment period may not capture long-term effects or durability of the intervention. Additionally, the use of a single tACS protocol (10 Hz) limits the ability to determine the optimal stimulation parameters for different patient populations.
Conclusion
This randomized controlled trial demonstrates that transcranial alternating current stimulation is an effective and well-tolerated intervention for the treatment of major depressive disorder. The significant improvements in remission rates and secondary outcome measures support the potential of tACS as a valuable addition to the therapeutic armamentarium for MDD. Future research should focus on optimizing stimulation parameters, exploring long-term outcomes, and identifying predictors of treatment response to further enhance the clinical utility of tACS.
doi.org/10.1097/CM9.0000000000000763
Was this helpful?
0 / 0